Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

1
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019

• Aarkstore Enterprise specialize in providing
  online market business information on market
  research reports, books, magazines, conference
  booking at competitive prices, and strive to
  provide excellent and innovative service to our
  customers.

2
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019

• Date 7 June 2012
• Pages 112
• SummaryMethicillin-resistant Staphylococcus
  aureus (MRSA) Therapeutics - Pipeline Assessment
  and Market Forecasts to 2019. The report is an
  essential source of information and analysis on
  the global Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics market. The report
  identifies the key trends shaping and driving the
  global Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics market. The report
  also provides insights on the prevalent
  competitive landscape and the emerging players
  expected to significantly alter the market
  positioning of the current market leaders. Most
  importantly, the report provides valuable
  insights on the pipeline products within the
  global Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics sector. This report is
  built using data and information sourced from
  proprietary databases, primary and secondary
  research and in-house analysis by GlobalDatas
  team of industry experts.ScopeThe report
  provides information on the key drivers and
  challenges of the Methicillin-Resistant
  Staphylococcus Aureus (MRSA) Therapeutics market.
  Its scope includes - - Annualized seven key
  markets (US, France, Germany, Italy, Spain, UK
  and Japan) Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics market revenues data
  from 2006 to 2011, forecast for eight years to
  2019. - Pipeline analysis data providing a split
  across the different phases, mechanisms of action
  being developed and emerging trends by seven key
  markets. Pipeline candidates fall under major
  therapeutic classes.- Analysis of the current
  and future competition in the seven key countries
  Methicillin-Resistant Staphylococcus Aureus
  (MRSA) Therapeutics market. - Insightful review
  of the key industry drivers, restraints and
  challenges. Each trend is independently
  researched to provide a qualitative analysis of
  its implications. - Key topics covered include
  strategic competitor assessment, market
  characterization, unmet needs and the
  implications for the Methicillin-Resistant
  Staphylococcus Aureus (MRSA) Therapeutics
  market.- Analysis of key recent licensing and
  partnership agreements in Methicillin-Resistant
  Staphylococcus Aureus (MRSA) Therapeutics market 

3
Methicillin-resistant Staphylococcus aureus
(MRSA) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019

• Reasons to buyThe report will enhance your
  decision making capability. It will allow you to
  - - Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies and by
  identifying the companies with the most robust
  pipeline. - Develop business strategies by
  understanding the trends shaping and driving the
  global Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics market. - Drive
  revenues by understanding the key trends,
  innovative products and technologies, market
  segments and companies likely to impact the
  global Methicillin-Resistant Staphylococcus
  Aureus (MRSA) Therapeutics market in future. -
  Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analyzing the performance of
  various competitors. - Identify emerging players
  with potentially strong product portfolios and
  create effective counter-strategies to gain a
  competitive advantage. - Organize your sales and
  marketing efforts by identifying the market
  categories and segments that present maximum
  opportunities for consolidations, investments and
  strategic partnerships. - Whats the next big
  thing in the global Methicillin-Resistant
  Staphylococcus Aureus (MRSA) Therapeutics market
  landscape? Identify, understand and
  capitalize. 

4
1.1 List of Tables 51.2 List of Figures 62
Methicillin - resistant Staphylococcus aureus
(MRSA) Therapeutics - Introduction 82.1 Overview
82.1.1 Hospital-acquired MRSA (HA-MRSA) 82.1.2
Community-acquired MRSA (CA-MRSA) 82.1.3
Historical Aspect of MRSA Infection 92.1.4
Genetic Variance between CA-MRSA and HA-MRSA
92.2 Epidemiology 112.2.1 Historic
Epidemiology  (2006-2011) 112.2.2 Forecasted
Epidemiology  (2011-2019) 112.3 Prognosis 132.4
Etiology 132.5 Symptoms 142.6 Diagnosis
152.6.1 Bacterial Culture 152.6.2 ChromAgar
Technique 152.6.3 Latex Agglutination Test
152.6.4 Molecular Detection 152.7
Pathophysiology 162.7.1 Molecular Pathogenesis
of MRSA 162.7.2 Mechanism of Resistance 182.7.3
Transmission of MRSA 182.8 Treatment and
Management Pattern 192.9 Referral Pathway
222.10 GlobalData Pipeline Report Guidance 233
Methicillin - resistant Staphylococcus aureus
(MRSA) Therapeutics - Market Characterization
243.1 MRSA Therapeutics Market Size (2006-2011)
- Global 243.2 MRSA Therapeutics Market Forecast
(2011-2019) - Global 263.3 MRSA Therapeutics
Market Size (2006-2011) - The US 283.4 MRSA
Therapeutics Market Forecast (2011-2019) - The US
293.5 MRSA Therapeutics Market Size (2006-2011)
- France 303.6 MRSA Therapeutics Market Forecast
(2011-2019) - France 313.7 MRSA Therapeutics
Market Size (2006-2011) - Germany 323.8 MRSA
Therapeutics Market Forecast (2011-2019) -
Germany 33
5

3.9 MRSA Therapeutics Market Size (2006-2011) -
Italy 353.10 MRSA Therapeutics Market Forecast
(2011-2019) - Italy 363.11 MRSA Therapeutics
Market Size (2006-2011) - Spain 383.12 MRSA
Therapeutics Market Forecast (2011-2019) - Spain
393.13 MRSA Therapeutics Market Size (2006-2011)
- The UK 413.14 MRSA Therapeutics Market
Forecast (2011-2019) - The UK 423.15 MRSA
Therapeutics Market Size (2006-2011) - Japan
443.16 MRSA Therapeutics Market Forecast
(2011-2019) - Japan 453.17 Drivers and Barriers
for the MRSA Therapeutics Market 463.17.1
Drivers for the MRSA Therapeutics Market
463.17.2 Barriers for the MRSA Therapeutics
Market 463.18 Opportunity and Unmet Need 483.19
Key Takeaway 514 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics - -
Competitive Assessment 524.1 Overview 524.2
Strategic Competitor Assessment 524.3 Product
Profile for the Major Marketed Products in the
MRSA Therapeutics Market 544.3.1 Zyvox
(linezolid) 544.3.2 Cubicin (daptomycin)
554.3.3 Tygacil (tigecycline) 574.3.4 Vibativ
(telavancin) 584.3.5 Teflaro (ceftaroline)
594.3.6 Vancocin (vancomycin) 614.4 Key
Takeaway 635 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Pipeline Assessment 645.1 Overview 645.2
Strategic Pipeline Assessment 645.3 MRSA
Therapeutics- Pipeline Analysis by Phase of
Development 655.3.1 MRSA Therapeutics- Phase III
Pipeline 655.3.2 MRSA Therapeutics- Phase II
Pipeline 665.3.3 MRSA Therapeutics- Phase I
Pipeline 675.3.4 MRSA Therapeutics- Pre-Clinical
Pipeline 685.3.5 MRSA Therapeutics- Discovery
Pipeline 69
6

5.3.6 MRSA Therapeutics- Unknown Phase Pipeline
705.4 MRSA Therapeutics- Pipeline by Mechanism
of Action 715.5 Technology Trends Analytical
Framework 735.6 Most Promising Drug Profiles
745.6.1 Torezolid phosphate (TR-701, Tedizolid)
745.6.2 Ceftobiprole Medocaril 755.6.3
Dalbavancin 765.6.4 Oritavancin 775.7 Key
Takeaway 776 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics
-Clinical Trials Mapping 786.1 Clinical Trials
by Region and Country 786.2 Clinical Trials by
Phase of Clinical Development 796.3 Clinical
Trials by Trial Status 806.4 Clinical Trials by
Sponsors 816.5 Top Companies Participating in
MRSA Clinical Trials 837 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Strategic Assessment 847.1 Key Events Impacting
the Future Market 847.2 Future Market
Competition Scenario 858 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Future Players 878.1 Introduction 878.2 Company
Profiles 888.2.1 Basilea Pharmaceutica Ltd.
888.2.2 Durata Therapeutics, Inc. 898.2.3 The
Medicines Company 898.2.4 Trius Therapeutics,
Inc. 908.2.5 AstraZeneca PLC 918.2.6
GlaxoSmithKline plc 938.2.7 Rib-X
Pharmaceuticals, Inc. 948.2.8 Wockhardt Limited
958.3 Details of Other Companies in the Pipeline
978.4 Key Takeaway 1009 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Licensing and Partnership Deals 10110 KOL
Insights 10411 Methicillin - resistant
Staphylococcus aureus (MRSA) Therapeutics -
Appendix 10511.1 Definitions 10511.2
Abbreviations 105
7

• For more information, please visit
• http//www.aarkstore.com/reports/Methicillin-resis
  tant-Staphylococcus-aureus-MRSA-Therapeutics-Pipel
  ine-Assessment-and-Market-Forecasts-to-2019-209429
  .htmlOr email us at contact_at_aarkstore.com or
  call 919272852585
• Related Reports
• Vemurafenib - Comprehensive patent
  search Colesevelam - Comprehensive patent
  search Rifaximin - Comprehensive patent
  search Nevirapine - Comprehensive patent
  search Liraglutide - Comprehensive patent
  search Vilazodone - Comprehensive patent
  search Hexylaminolevulinic Acid - Comprehensive
  patent search Treprostinil - Comprehensive
  patent search Patient Adherence, Communication
  and Engagement (PACE) - Increased Investment and
  Adoption of New Digital Tools Enable Key
  Stakeholder Collaborations and Encourage
  Compliance Express Scripts, Inc.
  Pharmaceuticals and Healthcare Company Profile,
  SWOT and Financial Report

8
Contact Us

• Aarkstore Enterprise
• Tel [phone]
• Mobile No08149852585
• Email contact_at_aarkstore.com
• Website http//www.aarkstore.com
• Blog http//www.emarketreports.com
• http//teju-aarkstoreenterprise.blogspot.in
• Follow us on twitter http//twitter.com/aarkstore
  dotcom
• http//in.linkedin.com/in/aarkstore
• http//www.facebook.com/aarkstoreenterprise